Pharmacological treatment for memory disorder in multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  He, Dian ^a   Zhang, Yun ^b   Dong, Shuai ^b   Wang, Dongfeng ^b   Gao, Xiangdong ^b   Zhou, Hongyu ^c  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b No 6 People's Hospital of Jinan   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; PLACEBO; CARBAMIC ACID DERIVATIVE; INDAN DERIVATIVE; MEMANTINE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; RIVASTIGMINE;

ABNORMAL DREAMING; BUSCHKE SELECTIVE REMINDING TEST; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEMORY DISORDER; MEMORY TEST; META ANALYSIS; MULTIPLE SCLEROSIS; NAUSEA; OUTCOME ASSESSMENT; PACED AUDITORY SERIAL ADDITION TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECALL; REVIEW; SPATIAL RECALL TEST; SYMBOL DIGIT MODALITIES TEST; SYSTEMATIC REVIEW; TREATMENT PLANNING; ADULT; GINKGO BILOBA; METHODOLOGY; MIDDLE AGED; PHYTOTHERAPY;

ADULT; GINKGO BILOBA; HUMANS; INDANS; MEMANTINE; MEMORY DISORDERS; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PHYTOTHERAPY; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84896038900     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008876.pub3     Document Type: Review

References (135)

1. Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004;63(9):1579-85.
2. Krupp LB, Christodoulou C, Melville P, Scherl WF, Pai LY, Muenz LR, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology 2011;76(17):1500-7.
3. Lovera J, Bagert B, Smoot K, Morris CD, Frank R, Bogardus K, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Multiple Sclerosis 2007;13(3):376-85.
4. Lovera JF, Frohman E, Brown TR, Bandari D, Nguyen L, Yadav V, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Multiple Sclerosis 2010;16(6):715-23.
5. Lovera JF, Kim E, Heriza E, Fitzpatrick M, Hunziker J, Turner AP, et al. Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial. Neurology 2012;79(12):1278-84.
6. Mäurer M, Ortler S, Baier M, Meergans M, Scherer P, Hofmann W, et al. Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. Multiple Sclerosis 2013;19(5):631-8.
7. Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Canadian Journal of Neurological Sciences 2008;35(4):476-81.
8. Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clinical Neuropharmacology 2009;32(1):41-7.
9. Barak Y, Gabbay U, Gilad R, Sarova-Pinhas I, Achiron A. Neuropsychiatric assessment as a secondary outcome measure in a multiple sclerosis intravenous immunoglobulin (IVIg) trial. International Journal of Psychiatry in Clinical Practice 1999;3:31-4.
10. Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. European Neurology 2002;47(1):11-4.
11. Benedict RH, Munschauer F, Zarevics P, Erlanger D, Rowe V, Feaster T, et al. Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. Journal of Neurology 2008;255(6):848-52.
12. Bever CT Jr, Anderson PA, Leslie J, Panitch HS, Dhib-Jalbut S, Khan OA, et al. Treatment with oral 3, 4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996;47(6):1457-62.
13. Bosca I, Bueno A, Gadea M, Casanova B, Coret F. Donepezile and cognitive impairment in multiple sclerosis: a double-blind pilot study. Multiple Sclerosis 2004;10(Suppl 2):S150.
14. Bruce J, Hancock L, Roberg B, Brown A, Henkelman E, Lynch S. Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study. Cognitive and Behavioral Neurology 2012;25(3):107-14.
15. Cabrera-Gomez JA, Echazabal-Santana N, Porrero-Martin P, Valenzuela-Silva C, Rodriguez CA, Fuentes-Suarez I, et al Interferon-alpha2b recombinant improved the cognitive dysfunction in patients with relapsing remitting multiple sclerosis. Revista de Neurologia 2003;37(3):214-20.
16. Christodoulou C, Melville P, Scherl WF, Macallister WS, Elkins LE, Krupp LB. Effects of donepezil on memory and cognition in multiple sclerosis. Journal of Neurological Sciences 2006;245(1-2):127-36.
17. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Archives of Neurology 1989;46(6):676-80.
18. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59(5):679-87.
19. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine 2010;362(5):402-15.
20. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, et al.Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine 2012;366(11):1000-9.
21. Decoo D, on behalf of the MS Rehab Study Group. Effects of donepezil in multiple sclerosis: a single-centre trial. Multiple Sclerosis 2004;10(Suppl 2):S150.
22. Fischer JS, Goodkin DE, Rudick RA, Perkins KK, Barilla DY, Daughtry MM, et al. Low dose (7.5 mg) oral methotrexate improves neurophysiological function in patients with chronic progressive multiple sclerosis. Annals of Neurology 1994;36:289.
23. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Annals of Neurology 2000;48(6):885-92.
24. Flechter S, Vardi J, Finkelstein Y, Pollak L. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. The Israel Medical Association Journal 2007;9(6):457-9.
25. Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology 1996;53(2):185-8.
26. Greene YM, Tariot PN, Wishart H, Cox C, Holt CJ, Schwid S, et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. Journal of Clinical Psychopharmacology 2000;20(3):350-6.
27. Harel Y, Appleboim N, Lavie M, Achiron A. Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. Journal of Neurological Sciences 2009;276(1-2):38-40.
28. Havrdova E. The effects of natalizumab on a test of cognitive function in patients with relapsing multiple sclerosis (MS) [abstract]. European Journal of Neurology 2006;13(Suppl 2):307.
29. Honarmand K, Tierney MC, O'Connor P, Feinstein A. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology 2011;76(13):1153-60.
30. Huolman S, Hämäläinen P, Vorobyev V, Ruutiainen J, Parkkola R, Laine T, et al. The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Multiple Sclerosis 2011;17(11):1351-61.
31. Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, Goretti B, et al. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. PLoS One 2012;7(4):e35843.
32. Jeffery D, Comi G, Kappos L, Montalban X, Boyko A, Filippi M. Laquinimod's impact on patient-reported fatigue and functional status: results from Allegro, a placebo-controlled phase III trial for relapsing-remitting multiple sclerosis. Multiple Sclerosis 2011;17:S313-4.
33. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine 2010;362(5):387-401.
34. Krause I, Kern S, Schultheiss T, Horntrich A, Hanso H, Thomas K, et al. Cognitive dysfunction in relapsing-remitting multiple sclerosis: relation to quality of life and longitudinal changes under treatment with natalizumab. Multiple Sclerosis 2012;18:S46.
35. Krupp LB, Elkins LE, Scheffer S, Smiroldo J, Coyle PK. Donepezil for the treatment of memory impairments in multiple sclerosis. Neurology 1999;52(Suppl 2):A137.
36. Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Multiple Sclerosis 2013;19(13):1765-72.
37. Lang C, Reiss C, Mäurer M. Natalizumab may improve cognition and mood in multiple sclerosis. European Neurology 2012;67(3):162-6.
38. Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue. Journal of Neurology 2009;256(4):645-50.
39. Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurological Sciences 2011;32(1):83-8.
40. Mattioli F, Stampatori C, Bellomi F, Capra R. Natalizumab efficacy on cognitive impairment in MS. Neurological Sciences 2011;31(Suppl 3):321-3.
41. Melanson M, Grossberndt A, Klowak M, Leong C, Frost EE, Prout M, et al. Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon beta. International Journal of Neuroscience 2010;120:631-40.
42. Miller A, O'Connor P, Wolinsky J, Confavreux C, Comi G, Kappos L, et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase III trial (TEMSO). Multiple Sclerosis 2011;17:S182.
43. Möller F, Poettgen J, Broemel F, Neuhaus A, Daumer M, Heesen C. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Multiple Sclerosis 2011;17(8):1002-9.
44. Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Multiple Sclerosis 2009;15(10):1195-205.
45. Morrow SA, Kaushik T, Zarevics P, Erlanger D, Bear MF, Munschauer FE, et al. The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. Journal of Neurology 2009;256(7):1095-102.
46. Morrow SA, Smerbeck A, Patrick K, Cookfair D, Weinstock-Guttman B, Benedict RH. Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. Journal of Neurology 2013;260(2):489-97.
47. Oliveri RL, Sibilia G, Valentino P, Russo C, Romeo N, Quattrone A. Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica 1998;97(6):366-9.
48. Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63(10):1788-95.
49. Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Lijoi F, et al. Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing-remitting multiple sclerosis: 2-year results from the COGIMUS study. Therapeutic Advances in Neurological Disorders 2009;2(2):67-77.
50. Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis 2010;16(1):68-77.
51. Pliskin NH, Towle VL, Hamer DP, Reder AT, Noronha A, Pietre S, et al. The effects of interferon-beta on cognitive function in multiple sclerosis. Annals of Neurology 1994;36:326.
52. Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996;47(6):1463-8.
53. Portaccio E, Stromillo ML, Goretti B, Hakiki B, Giorgio A, Rossi F, et al. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study. European Journal of Neurology 2013;20(6):986-90.
54. Rorie KD, Stump DA, Jeffery DR, Winston Salem NC. Effects of donepezil on cognitive function in patients with multiple sclerosis. Neurology 2001;56(Suppl 3):A99.
55. Rossini PM, Pasqualetti P, Pozzilli C, Grasso MG, Millefiorini E, Graceffa A, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Multiple Sclerosis 2001;7(6):354-8.
56. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New England Journal of Medicine 2006;354(9):911-23.
57. Sailer M, Heinze HJ, Schoenfeld MA, Hauser U, Smid HG. Amantadine influences cognitive processing in patients with multiple sclerosis. Pharmacopsychiatry 2000;33(1):28-37.
58. Schröder A, Klotz P, Lee DH, Gold R, Linker RA. Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis. Clinical Neurology and Neurosurgery 2011;113(7):527-30.
59. Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP for the Copaxone Study Group. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. Journal of Neurological Sciences 2007;255(1-2):57-63.
60. Selby MJ, Ling N, Williams JM, Dawson A. Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis. Perceptual and Motor Skills 1998;86(3 Pt 1):1099-106.
61. Selmaj K, Havrdova E, Gold R, Greenberg S, Umans K, Elkins J. Daclizumab Hyp monotherapy improved health-related quality of life parameters in relapsing-remitting multiple sclerosis: findings of the SELECT trial. Neurology 2012; Vol. 78.
62. Smits RC, Emmen HH, Bertelsmann FW, Kulig BM, van Loenen AC, Polman CH. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 1994;44(9):1701-5.
63. Sumowski JF, Chiaravalloti N, Erlanger D, Kaushik T, Benedict RH, DeLuca J. L-amphetamine improves memory in MS patients with objective memory impairment. Multiple Sclerosis 2011;17(9):1141-5.
64. Uttner I, Müller S, Zinser C, Maier M, Süssmuth S, Claus A, et al. Reversible impaired memory induced by pulsed methylprednisolone in patients with MS. Neurology 2005;64(11):1971-3.
65. Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009;72(19):1630-3.
66. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis 2004;10(4):434-41.
67. Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Archives of Neurology 1999;56(3):319-24.
68. Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology 2012;259(5):898-905.
69. Weinstock-Guttman B, Cree B, de Seze J, Fox R, Gold R, Hartung H, et al. Effects of a 24-week natalizumab treatment interruption on quality of life, fatigue, and cognition: results from the RESTORE Study. Neurology 2012; Vol. 78:P06.171.
70. Wilken J, Kane R, Sullivan C, Kane H, Rossman S, Lawson J, et al. Combination therapy (Provigil + Avonex) in the treatment of cognitive problems in MS [abstract]. International Journal of MS Care 2004;6:68-9.
71. Wilken JA, Sullivan C, Wallin M, Rogers C, Kane RL, Rossman H, et al. Treatment of multiple sclerosis-related cognitive problems with adjunctive modafinil: rationale and preliminary supportive data. International Journal of MS Care 2008;10:1-10.
72. Zéphir H, de Seze J, Dujardin K, Dubois G, Cabaret M, Bouillaguet S, et al.One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. Multiple Sclerosis 2005;11(3):360-3.
73. Zéphir H, de Sèze J, Dujardin K, Dubois G, Cabaret M, Bouillaguet S, et al. Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study. Revue Neurologique (Paris) 2008;164(1):47-52.
74. NCT01074619 Study on cognitive disorders of multiple sclerosis. clinicaltrials.gov/ct2/show/NCT01074619 (accessed 10 December 201).
75. NCT01466114 Estriol treatment in multiple sclerosis (MS): effect on cognition. clinicaltrials.gov/ct2/show/NCT01466114 (accessed 10 December 2013).
76. Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cellular Molecular Life Sciences 2003;60:1779-92.
77. Amato MP, Bartolozzi ML, Zipoli V, Portaccio E, Mortilla M, Guidi L, et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 2004;63(1):89-93.
78. Amato MP, Portaccio E, Zipoli V. Are there protective treatments for cognitive decline in MS?. Journal of the Neurological Sciences 2006;245(1-2):183-6.
79. Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Multiple Sclerosis 2003;9(3):219-27.
80. Benedict R. Brief Visuospatial Memory Test-Revised: Professional Manual. Odessa, Florida: Psychological Assessment Resources, 1997.
81. Benedict RH, Zivadinov R, Carone DA, Weinstock-Guttman B, Gaines J, Maggiore C, et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. American Journal of Neuroradiology 2005;26(7):1824-31.
82. Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). Journal of the International Neuropsychological Society 2006;12(4):549-58.
83. Benedict RH, Ramasamy D, Munschauer F, Weinstock-Guttman B, Zivadinov R. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. Journal of Neurology Neurosurgery and Psychiatry 2009;80(2):201-6.
84. Boringa JB, Lazeron RH, Reuling IE, Adèr HJ, Pfennings L, Lindeboom J, et al. The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Multiple Sclerosis 2001;7(4):263-7.
85. Buschke H, Fuld PA. Evaluating storage, retention and retrieval in disordered memory and learning. Neurology 1974;24:1019-25.
86. Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Archives of Neurology 2009;66(9):1144-50.
87. Calabrese M, Poretto V, Favaretto A, Alessio S, Bernardi V, Romualdi C, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 2012;135(Pt 10):2952-61.
88. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47(1):129-39.
89. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurology 2008;7(12):1139-51.
90. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test. 2nd Edition. San Antonio: Psychological Corporation, 2000.
91. DineenRA, Vilisaar J, Hlinka J, Bradshaw CM, Morgan PS, Constantinescu CS, et al. Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. Brain 2009;132(Pt 1):239-49.
92. Feuillet L, Reuter F, Audoin B, Malikova I, Barrau K, Cherif AA, et al. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis 2007;13(1):124-7.
93. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Multiple Sclerosis 1999;5(4):251-9.
94. Foong J, Rozewicz L, Quaghebeur G, Thompson AJ, Miller DH, Ron MA. Neuropsychological deficits in multiple sclerosis after acute relapse. Journal of Neurology Neurosurgery and Psychiatry 1998;64(4):529-32.
95. Geurts JJ, Calabrese M, Fisher E, Rudick RA. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurology 2012;11(12):1082-92.
96. Glanz BI, Healy BC, Hviid LE, Chitnis T, Weiner HL. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. Journal of Neurology Neurosurgery and Psychiatry 2012;83(1):38-43.
97. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
98. Huang SH, Duke RK, Chebib M, Sasaki K, Wada K, Johnston GA. Ginkgolides, diterpene trilactones of Ginkgo biloba, as antagonists at recombinant alpha1beta2gamma2L GABAA receptors. European Journal of Pharmacology 2004;494:131-8.
99. Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Reuling IE, Polman CH. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 2004;63(2):335-9.
100. Kinsinger SW, Lattie E, Mohr DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology 2010;24(5):573-80.
101. Kuczenski R, Segal DS, Cho AK, Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. The Journal of Neuroscience 1995;15:1308-17.
102. Leocani L, Locatelli T, Martinelli V, Rovaris M, Falautano M, Filippi M, et al. Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. Journal of Neurology Neurosurgery and Psychiatry 2000;69(2):192-8.
103. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th Edition. New York: Oxford University Press, 2004.
104. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology 2001;50(1):121-7.
105. Mesaros S, Rocca MA, Kacar K, Kostic J, Copetti M, Stosic-Opincal T, et al. Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis. Neurology 2012;78(13):969-75.
106. Morgen K, Sammer G, Courtney SM, Wolters T, Melchior H, Blecker CR, et al. Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. Neuroimage 2006;30(3):891-8.
107. Morrow SA, Jurgensen S, Forrestal F, Munchauer FE, Benedict RH. Effects of acute relapses on neuropsychological status in multiple sclerosis patients. Journal of Neurology 2011;258(9):1603-8.
108. Nathan P. Can the cognitive enhancing effects of Ginkgo biloba be explained by its pharmacology?. Medical Hypotheses 2000;55:491-93.
109. Paulesu E, Perani D, Fazio F, Comi G, Pozzilli C, Martinelli V, et al. Functional basis of memory impairment in multiple sclerosis: a [18F] FDG PET study. Neuroimage 1996;4(2):87-96.
110. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nature Medicine 2000;6(1):67-70.
111. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology 2005;58(6):840-6.
112. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology 2011;69(2):292-302.
113. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983;13(3):227-31.
114. Potagas C, Giogkaraki E, Koutsis G, Mandellos D, Tsirempolou E, Sfagos C, et al. Cognitive impairment in different MS subtypes and clinically isolated syndromes. Journal of the Neurological Sciences 2008;267(1-2):100-6.
115. Rao SM, in collaboration with the Cognitive Function Study Group of the National Multiple Sclerosis Society. A Manual for the Brief, Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. Milwaukee: WI: Section of Neuropsychology, Medical College of Wisconsin, 1990.
116. Rao SM. Cognitive Function Study Group, NMSS. A Manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. New York: National Multiple Sclerosis Society, 1990.
117. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41(5):685-91.
118. Rao SM, Leo GJ, Ellington MS, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: II. Impact on employment and social functioning. Neurology 1991;41:692-6.
119. Rao SM. Neuropsychological Screening Battery for Multiple Sclerosis. Milwaukee, WI: Medical College of Wisconsin, 1991.
120. Rao SM, Grafman J, DiGiulio D, Mittenberg W, Bernardin L, Leo GJ, et al. Memory dysfunction in multiple sclerosis: its relation to working memory, semantic encoding, and implicit learning. Neuropsychology 1993;7(3):364-74.
121. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
122. Rossi F, Giorgio A, Battaglini M, Stromillo ML, Portaccio E, Goretti B, et al. Relevance of brain lesion location to cognition in relapsing multiple sclerosis. PLoS One 2012;7(11):e44826.
123. Ruberg M, Villageois A, Bonnet AM, Rieger F, Agid Y, Fahn S. Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems. Journal of Neurology Neurosurgery and Psychiatry 1987;50(5):538-43.
124. Ruet A, Deloire M, Charré-Morin J, Hamel D, Brochet B. Cognitive impairment differs between primary progressive and relapsing-remitting MS. Neurology 2013;80(16):1501-8.
125. Sanfilipo MP, Benedict RH, Weinstock-Guttman B, Bakshi R. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology 2006;66(5):685-92.
126. Schünemann H, Broz˙ek J, Oxman A, editors. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendation. Version 3.2 [updated March 2009]. The GRADE Working Group. http://www.cc-ims-net/gradepro 2009.
127. Smith, A Symbol Digit Modalities Test (SDMT). Los Angeles: Western Psychological Services, 1982.
128. Thornton AE, Raz N, Tucke KA. Memory in multiple sclerosis: contextual encoding deficits. Journal of the International Neuropsychological Society 2002;8(3):395-409.
129. Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P. Grey matter pathology in multiple sclerosis. Journal of Neuropathology and Experimental Neurology 2005;64(12):1101-7.
130. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Quality of Life Research 1995;4(3):187-206.
131. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83.
132. Wechsler D. Wechsler Memory Scale-Revised. San Antonio: Psychological Corporation, 1987.
133. Wechsler D. Wechsler Memory Scale - Third Edition (WMS-III). San Antonio: Psychological Corporation, 1997.
134. Wechsler D. Wechsler Adult Intelligence Scale. 3rd Edition. San Antonio: The Psychological Corporation, 1997.
135. He D, Zhou H, Guo D, Hao Z, Wu B. Pharmacologic treatment for memory disorder in multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD008876]